Dr. Jonathan Trent on Engineered T- cell Therapy in Sarcoma

Jonathan C. Trent, MD, PhD
Published: Friday, Jul 08, 2016



Jonathan C. Trent, MD, PhD, professor of medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses T-cell therapies in sarcoma.

Many types of sarcomas have translocations and point mutations that lead to novel antigens that can be specifically recognized by an engineered T cell, says Trent.  
 
There are also several types of sarcoma, such as synovial sarcoma and liposarcoma that express testicular antigens—such as NY-ESO-1—that are not expressed in any other cell in the human body. These neoantigens can be targets of modified T-cells, such as the T-cells that are now being engineered by a number of different companies to bind to and kill NY-ESO-1 in synovial sarcoma and liposarcoma cells.
 
Clinical trials are available investigating these agents.
 
 
SELECTED
LANGUAGE


Jonathan C. Trent, MD, PhD, professor of medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses T-cell therapies in sarcoma.

Many types of sarcomas have translocations and point mutations that lead to novel antigens that can be specifically recognized by an engineered T cell, says Trent.  
 
There are also several types of sarcoma, such as synovial sarcoma and liposarcoma that express testicular antigens—such as NY-ESO-1—that are not expressed in any other cell in the human body. These neoantigens can be targets of modified T-cells, such as the T-cells that are now being engineered by a number of different companies to bind to and kill NY-ESO-1 in synovial sarcoma and liposarcoma cells.
 
Clinical trials are available investigating these agents.
 
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x